Journal article
Conditional immune adverse event rate in urothelial and renal cell carcinoma patients treated with immune checkpoint inhibitors.
Abstract
481
Background: Immune checkpoint inhibitors (ICIs) are associated with immune-related adverse events (irAEs). While the incidence and prevalence of irAEs have been well characterized in the literature, much less is known about the cumulative incidence (CI) rate of irAEs. We sought to evaluate the CI of irAEs in metastatic urothelial carcinoma (mUC) and metastatic renal cell carcinoma (mRCC) patients (pts) treated with ICIs. …
Authors
Nuzzo PV; Pond GR; Abou Alaiwi S; Nassar A; Flippot R; Curran C; Kilbridge KL; Wei XX; McGregor BA; Harshman LC
Journal
Journal of Clinical Oncology, Vol. 38, No. 6_suppl, pp. 481–481
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
February 20, 2020
DOI
10.1200/jco.2020.38.6_suppl.481
ISSN
0732-183X